利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.018 秒)

    Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
    1.
    发明授权
    Cyclic amine derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists 失效
    取代喹喔啉2,3-二酮的环胺衍生物作为谷氨酸受体拮抗剂

    公开(公告)号：US6110911A

    公开(公告)日：2000-08-29

    申请号：US272482

    申请日：1999-03-19

    申请人： Brian Edward Kornberg ,  Sham Shridhar Nikam ,  Michael Francis Rafferty ,  Po-Wai Yuen

    发明人： Brian Edward Kornberg ,  Sham Shridhar Nikam ,  Michael Francis Rafferty ,  Po-Wai Yuen

    IPC分类号： C07D241/44 ,  A61K31/4985 ,  A61K31/55

    CPC分类号： C07D241/44

    摘要： A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

    摘要翻译： 教导了一系列用作神经保护剂的取代喹喔啉2,3-二酮。 还教导了新的中间体，制备方法和含有这些化合物的药物组合物。 这些化合物是谷氨酸拮抗剂，可用于治疗由血栓栓塞或出血性脑卒中，脑血管痉挛，低血糖症，心脏骤停，癫痫持续状态，围产期窒息，缺氧，癫痫发作，疼痛，阿尔茨海默病， 帕金森病和亨廷顿疾病。

    Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
    2.
    发明授权
    Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists 失效
    哌啶衍生物作为亚型选择性N-甲基-D-天冬氨酸拮抗剂

    公开(公告)号：US06642256B2

    公开(公告)日：2003-11-04

    申请号：US09998479

    申请日：2001-11-30

    申请人： Brian Edward Kornberg ,  Russell Andrew Lewthwaite ,  David Manning ,  Sham Shridhar Nikam ,  Ian Leslie Scott

    发明人： Brian Edward Kornberg ,  Russell Andrew Lewthwaite ,  David Manning ,  Sham Shridhar Nikam ,  Ian Leslie Scott

    IPC分类号： A01N4340

    CPC分类号： C07D413/14 ,  C07D417/14

    摘要： Described are piperidines of Formula I and pharmaceutically acceptable salts thereof. The compounds of Formula I are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, central nervous system disorders, depression, trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, pain, especially chronic pain, neuropathic pain, or surgical pain, or urinary incontinence.

    摘要翻译： 描述了式I的哌啶及其药学上可接受的盐。 式I的化合物是可用于治疗脑血管病症的NMDA受体通道复合物的拮抗剂，例如中风，脑缺血，中枢神经系统疾病，抑郁症，创伤，低血糖症，神经变性疾病，焦虑，偏头痛，抽搐， 帕金森病，氨基糖苷类抗生素诱导的听力损失，精神病，青光眼，CMV视网膜炎，阿片类药物耐受或戒断，疼痛，特别是慢性疼痛，神经性疼痛或手术疼痛或尿失禁。

    Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
    3.
    发明授权
    Sulfonamide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists 失效
    取代喹喔啉2,3-二酮的磺酰胺衍生物作为谷氨酸受体拮抗剂

    公开(公告)号：US6096744A

    公开(公告)日：2000-08-01

    申请号：US72117

    申请日：1998-05-04

    申请人： Brian Edward Kornberg ,  Sham Shridhar Nikam

    发明人： Brian Edward Kornberg ,  Sham Shridhar Nikam

    IPC分类号： C07D241/44 ,  A61K31/498

    CPC分类号： C07D241/44

    摘要： A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

    摘要翻译： 教导了一系列用作神经保护剂的取代喹喔啉2,3-二酮。 还教导了新的中间体，制备方法和含有这些化合物的药物组合物。 这些化合物是谷氨酸拮抗剂，可用于治疗由血栓栓塞或出血性脑卒中，脑血管痉挛，低血糖症，心脏骤停，癫痫持续状态，围产期窒息，缺氧，癫痫发作，疼痛，阿尔茨海默病， 帕金森病和亨廷顿疾病。

    Substituted quinoxaline-2-ones as glutamate receptor antagonists
    7.
    发明授权
    Substituted quinoxaline-2-ones as glutamate receptor antagonists 失效
    取代的喹喔啉-2-酮作为谷氨酸受体拮抗剂

    公开(公告)号：US06015800A

    公开(公告)日：2000-01-18

    申请号：US79668

    申请日：1998-05-15

    申请人： Sham Shridhar Nikam

    发明人： Sham Shridhar Nikam

    IPC分类号： C07D241/44 ,  C07D403/06 ,  A61K31/495 ,  C07D403/10

    CPC分类号： C07D403/06 ,  C07D241/44

    摘要： A novel series of substituted quinoxaline 2-ones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate receptor antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

    摘要翻译： 教导了一系列用作神经保护剂的取代喹喔啉2-酮。 还教导了新的中间体，制备方法和含有这些化合物的药物组合物。 这些化合物是谷氨酸受体拮抗剂，可用于治疗由血栓栓塞或出血性脑卒中，脑血管痉挛，低血糖症，心脏骤停，癫痫持续状态，围产期窒息，缺氧，癫痫发作，疼痛，阿尔茨海默氏症等引起的脑卒中，脑缺血或脑梗塞。 ，帕金森病和亨廷顿疾病。

    Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists
    9.
    发明授权
    Amide derivatives of substituted quinoxaline 2,3-diones as glutamate receptor antagonists 失效
    取代喹喔啉2,3-二酮的酰胺衍生物作为谷氨酸受体拮抗剂

    公开(公告)号：US06268366B1

    公开(公告)日：2001-07-31

    申请号：US09688731

    申请日：2000-10-16

    申请人： Sham Shridhar Nikam

    发明人： Sham Shridhar Nikam

    IPC分类号： A61K31498

    CPC分类号： C07D405/12 ,  C07D241/44 ,  C07D409/12

    摘要： A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate receptor antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

    摘要翻译： 教导了一系列用作神经保护剂的取代喹喔啉2,3-二酮。 还教导了新的中间体，制备方法和含有这些化合物的药物组合物。 这些化合物是谷氨酸受体拮抗剂，可用于治疗由血栓栓塞或出血性脑卒中，脑血管痉挛，低血糖症，心脏骤停，癫痫持续状态，围产期窒息，缺氧，癫痫发作，疼痛，阿尔茨海默氏症等引起的脑卒中，脑缺血或脑梗塞。 ，帕金森病和亨廷顿疾病。

    Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists
    10.
    发明授权
    Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists 失效
    环己胺衍生物作为亚型选择性N-甲基-D-天冬氨酸拮抗剂

    公开(公告)号：US06828341B2

    公开(公告)日：2004-12-07

    申请号：US10108086

    申请日：2002-03-27

    申请人： Russell Joseph DeOrazio ,  Sham Shridhar Nikam ,  Ian Leslie Scott ,  Brian Alan Sherer

    发明人： Russell Joseph DeOrazio ,  Sham Shridhar Nikam ,  Ian Leslie Scott ,  Brian Alan Sherer

    IPC分类号： C07D41304

    CPC分类号： C07D413/04 ,  C07D263/58 ,  C07D413/12 ,  C07D417/12

    摘要： Described are cyclohexylamine derivatives of Formula I and pharmaceutically acceptable salts thereof, wherein R1, g, *, R, V, B, E, Y, G, H, X1, and d are as defined in the description. The compounds of Formulas I, VI, and VIa are antagonists of NMDA receptor channel complexes useful for treating cerebral vascular disorders such as, for example, stroke, cerebral ischemia, trauma, hypoglycemia, anxiety, migraine headache, convulsions, Parkinson's disease, aminoglycoside antibiotics-induced hearing loss, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, chronic pain, or urinary incontinence.

    摘要翻译： 描述了式I的环己胺衍生物及其药学上可接受的盐，其中R1，g，*，R，V，B，E，Y，G，H，X1和d如说明书中所定义。 式I，VI和VIa的化合物是可用于治疗脑血管病症例如中风，脑缺血，创伤，低血糖，焦虑，偏头痛，抽搐，帕金森病，氨基糖苷类抗生素的NMDA受体通道复合物的拮抗剂 引起的听力损失，精神病，青光眼，CMV视网膜炎，阿片样物质耐受或戒断，慢性疼痛或尿失禁。